		Technical Data
D9099-45	Doxorubicin (DXR, 14-Hydroxydaunomycin, Adriamycin, Adriacin, Adriblastin, Caelyx, Dox, Doxil, Farmiblastina, FI 106, K 1039, KW 125, NSC 123127 )

Description:
Doxorubicin is the most extensively studied of a family of highly fluorescent anthracycline antibiotics produced by several Streptomyces species, first reported in 1967 and later approved for human therapeutic use as an antitumor agent for the treatment of a wide range of cancers. Doxorubicin has also been reported to exhibit anti-HIV and antibacterial activity. The mode of action of doxorubicin is thought to be due to intercalation of DNA and inhibition of nucleic acid synthesis.

Applications:
Suitable for use in ELISA, Immunohistochemistry and Functional Applications. Other applications have not been tested.

Recommended Dilutions:
Functional Applications: In vivo antidotic effect
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Type	Isotype	Clone	Grade
Mab	IgG2	6D359	Purified

Size		Storage	Shipping	Source	Host
100ug		-20°C	Blue Ice		Mouse

Concentration:

~1mg/ml

Immunogen:

Doxorubicin, conjugated to BSA.

Purity:

Purified

Form

Supplied as a liquid in 150mM sodium chloride, pH 7.4, 0.02% sodium azide.

Specificity:

Recognizes anthracycline compounds including doxorubicin analogs and derivatives.

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.

1. Monoclonal antibodies against doxorubicin: A. Balsari, et al.; Int. J. Cancer 42, 798 (1988) Abstracte: A. Balsari, et al.; Anticancer Res. 10, 129 (1990) 2. A. Balsari, et al.; Int. J. Cancer 47, 889 (1991) 3. A. Sardini, et al.; Int. J. Cancer 50, 617 (1992) 4. : A.L. Balsari, et al.; FASEB J. 8, 226 (1994) 5.: D. Morelli, et al.; Cell Biophys. 24-25, 119 (1994) 6. i, et al.; Scand. J. Immunol. 39, 453 (1994) 7. D. Morelli, et al.; Cancer Res. 56, 2082 (1996) 8. R. Cece, et al.; Lab. Invest. 75, 601 (1996) 9. Intratibial injection of an anti-doxorubicin monoclonal antibody prevents drug-induced myelotoxicity in mice: D. Morelli, et al.; Br. J. Cancer 75, 656 (1997) 10. A. Balsari, et al.; Br. J. Cancer 85, 1964 (2001) 11. M. Campiglio, et al.; Int. J. Cancer 105, 568 (2003)